CAS · 165800-06-6
Product Overview
Zoledronic acid hydrate is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Character: | White or off-white crystalline powder |
|---|---|
| Purity: | 99.7% min |
| Solubility: | Sparingly soluble in 0.1N sodium hydroxide solution, slightly soluble in water and 0.1N hydrochloric acid, practically insoluble in ethanol |
| Appearance of solution: | The solution should be clear and colorless; if opalescent, should not be more opalescent than reference suspension; if colored, not more intensely colored than Y2 |
| Identification: | IR Spectrum Sample should concordant with spectrum of standard |
| Acidity (pH): | 2.0 ~ 4.0 |
| Loss on drying: | 5.0% ~ 7.0% |
| Chloride: | 0.02% max |
| Phosphate: | 0.5% max |
| Phosphite: | 0.5% max |
| Heavy metals: | 0.001% max |
| Unknown single impurity: | 0.1% max |
| Total impurity: | 0.3% max |
Applications
1. Pharmaceuticals – Treatment of Bone Diseases
Zoledronic acid is approved for the treatment of multiple bone-related disorders, including:
Osteoporosis (postmenopausal, glucocorticoid-induced, and male osteoporosis)
Paget's disease of bone
Hypercalcemia of malignancy
Bone metastases from solid tumors (e.g., breast cancer, prostate cancer)
Multiple myeloma with bone lesions
2. Oncology Supportive Care
Reduces skeletal-related events (SREs) such as fractures, spinal compression, and bone pain in patients with bone metastases.
Used as an adjunct to cancer therapies to improve bone density and delay tumor progression in bone.
3. Research Use
Utilized in preclinical studies to investigate:
Bone remodeling
Osteoclast function and signaling
Tumor–bone interactions in metastatic models
Studied for potential anticancer effects beyond bone targeting, such as anti-angiogenic or pro-apoptotic activity.
Benefits
✅ High Potency
Zoledronic acid is one of the most potent bisphosphonates available. A once-yearly intravenous infusion is sufficient for osteoporosis treatment.
✅ Bone Targeting
Selectively binds to bone mineral matrix, especially at sites of active resorption, providing targeted therapeutic action.
✅ Improved Quality of Life
In cancer patients, helps maintain skeletal integrity, reduce pain, and delay complications.
✅ Long Duration of Action
Strong affinity for bone and slow release allow for extended therapeutic effects, reducing dosing frequency.
✅ Synergistic Use in Oncology
Shows potential for combination with chemotherapy and targeted therapy for improved patient outcomes.
Conclusion
Zoledronic acid hydrate (CAS 165800-06-6) is a clinically critical bisphosphonate used to preserve bone strength, prevent fractures, and manage bone complications in cancer. Its exceptional potency and long-acting profile make it a cornerstone in the treatment of osteolytic bone conditions and in oncology supportive care. It continues to be a focus of research for new therapeutic strategies in bone biology and cancer metastasis.
Previous
Next